Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
AuthorSpencer, A; Roberts, A; Kennedy, N; Ravera, C; Cremers, S; Bilic, S; Neeman, T; Copeman, M; Schran, H; Lynch, K
Source TitleBMC Clinical Pharmacology
PublisherSpringer Science and Business Media LLC
University of Melbourne Author/sRoberts, Andrew
AffiliationCentre for Cancer Research
Document TypeJournal Article
CitationsSpencer, A., Roberts, A., Kennedy, N., Ravera, C., Cremers, S., Bilic, S., Neeman, T., Copeman, M., Schran, H. & Lynch, K. (2008). Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.. BMC Clin Pharmacol, 8 (1), pp.2-. https://doi.org/10.1186/1472-6904-8-2.
Access StatusOpen Access
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2330021
BACKGROUND: Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy. METHODS: Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months. RESULTS: No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid pharmacokinetics or renal safety for up to 16 months in patients randomized to thalidomide or not. CONCLUSION: In myeloma patients receiving maintenance therapy, the combination of zoledronic acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References